MXPA03000182A - Efectividad terapeutica de mejoria de inhalacion de oxido nitrico. - Google Patents

Efectividad terapeutica de mejoria de inhalacion de oxido nitrico.

Info

Publication number
MXPA03000182A
MXPA03000182A MXPA03000182A MXPA03000182A MXPA03000182A MX PA03000182 A MXPA03000182 A MX PA03000182A MX PA03000182 A MXPA03000182 A MX PA03000182A MX PA03000182 A MXPA03000182 A MX PA03000182A MX PA03000182 A MXPA03000182 A MX PA03000182A
Authority
MX
Mexico
Prior art keywords
inhalation
effective amount
nitric oxide
administering
therapeutically effective
Prior art date
Application number
MXPA03000182A
Other languages
English (en)
Inventor
Kenneth Bloch
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of MXPA03000182A publication Critical patent/MXPA03000182A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen metodos para reducir, prevenir parcialmente o prevenir completamente el deterioro relacionado a la inhalacion de oxido nitrico (NO) de HPV en un mamifero. Los metodos incluyen administrar una cantidad terapeuticamente eficaz de NO por inhalacion, y co-administrar una cantidad eficaz de un agente de especie de oxigeno anti-reactivo (anti-ROS), por ejemplo, N-acetil-cisteina, o un bloqueador de leucotrieno. Tambien se describen metodos para reducir, prevenir parcialmente o prevenir completamente la perdida de sensibilidad vasodilatadora pulmonar a la inhalacion de NO en un mamifero. Los metodos incluyen administrar una cantidad terapeuticamente eficaz de NO por inhalacion, y co-administrar una cantidad eficaz de un agente anti-ROS, una cantidad terapeuticamente eficaz de un bloqueador de leucotrieno.
MXPA03000182A 2000-06-28 2001-06-22 Efectividad terapeutica de mejoria de inhalacion de oxido nitrico. MXPA03000182A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/605,900 US6601580B1 (en) 2000-06-28 2000-06-28 Enhancing therapeutic effectiveness of nitric oxide inhalation
PCT/US2001/041102 WO2002000175A2 (en) 2000-06-28 2001-06-22 Enhancing therapeutic effectiveness of nitric oxide inhalation

Publications (1)

Publication Number Publication Date
MXPA03000182A true MXPA03000182A (es) 2004-02-26

Family

ID=24425654

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000182A MXPA03000182A (es) 2000-06-28 2001-06-22 Efectividad terapeutica de mejoria de inhalacion de oxido nitrico.

Country Status (10)

Country Link
US (2) US6601580B1 (es)
EP (1) EP1301076A4 (es)
JP (1) JP2004509850A (es)
KR (1) KR100849103B1 (es)
CN (1) CN100488497C (es)
AU (2) AU2001273622B2 (es)
CA (1) CA2414409A1 (es)
IL (1) IL153702A0 (es)
MX (1) MXPA03000182A (es)
WO (1) WO2002000175A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7335181B2 (en) * 2000-12-26 2008-02-26 Pulmonox Technologies Corporation Nitric oxide decontamination of the upper respiratory tract
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
GB0125357D0 (en) * 2001-10-22 2001-12-12 Univ Brighton Improvements relating to catalytic antioxidants
WO2003045334A2 (en) * 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
CN1635882B (zh) * 2002-01-04 2010-11-10 桑得医药品公司 组合物在制备治疗听力丧失的药物中的用途
PL375161A1 (en) * 2002-06-21 2005-11-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
US9138707B2 (en) 2002-12-10 2015-09-22 Sy Kimball Portable, nitric oxide generator
SE0300971D0 (sv) * 2003-04-03 2003-04-03 Aga Ab Nitric oxide in treatment of inflammation
AU2004255268B2 (en) * 2003-07-09 2010-04-01 Loma Linda University Use of nitrite salts for the treatment of cardiovascular conditions
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
WO2005110441A2 (en) * 2004-05-11 2005-11-24 Sensormedics Corporation Intermittent dosing of nitric oxide gas
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
CA2600134A1 (en) * 2005-03-08 2006-09-14 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
WO2007057763A2 (en) * 2005-11-18 2007-05-24 Pulmonox Technologies Corporation Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
US8790715B2 (en) 2006-02-16 2014-07-29 Ino Therapeutics Llc Method and apparatus for generating nitric oxide for medical use
WO2007136789A2 (en) * 2006-05-19 2007-11-29 Medimmune, Inc. Methods of preventing, treating or ameliorating enhanced respiratory disease via innate immune mechanisms
FR2902002B1 (fr) * 2006-06-12 2010-08-27 Lvmh Rech Composition cosmetique anti-radicaux libres
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
JP5697335B2 (ja) * 2006-11-07 2015-04-08 ザ ジェネラル ホスピタル コーポレイション 血管作動性酸素運搬体に誘導される血管収縮の減弱
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
WO2009063226A2 (en) * 2007-11-12 2009-05-22 Karolinska Institutet Innovations Ab Methods relating to breathing disorders
JP2011507968A (ja) * 2007-12-27 2011-03-10 エイヤーズ ファーマシューティカルズ、インク． エアロゾル化ニトライトおよび一酸化窒素供与性化合物ならびにそれらの使用
US8720436B2 (en) * 2008-01-31 2014-05-13 Genosys, Inc. Nitric oxide gel apparatus and method
US9649467B2 (en) 2008-01-31 2017-05-16 Syk Technologies, Llc Nitric oxide reactor and distributor apparatus and method
US8434475B2 (en) * 2008-01-31 2013-05-07 Genosys, Inc. Nitric oxide reactor and distributor apparatus and method
US8501090B2 (en) * 2008-03-24 2013-08-06 Christian S. Minton Anti-microbial gas apparatus and method
CA3130908A1 (en) 2009-06-30 2010-12-30 Mallinckrodt Hospital Products IP Limited Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
JP5581500B2 (ja) 2010-03-10 2014-09-03 学校法人北里研究所 虚血再灌流障害軽減用治療剤および治療装置
US8685467B2 (en) 2010-08-03 2014-04-01 J. W. Randolph Miller Nitric oxide generation, dilution, and topical application apparatus and method
WO2012131412A2 (en) 2011-03-31 2012-10-04 Szabo Laszlo Gabor Pharmaceutical composition containing no, process for the preparation and use thereof
JP6389125B2 (ja) 2011-11-07 2018-09-12 ザ ジェネラル ホスピタル コーポレイション 赤血球の処理法
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
EP2908137A1 (en) * 2014-02-14 2015-08-19 Institut Pasteur Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s)
JP2014141536A (ja) * 2014-05-16 2014-08-07 Kitasato Institute 虚血再灌流障害軽減用治療剤および治療装置
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
CA3009986A1 (en) * 2015-12-28 2017-07-06 Vero Biotech LLC Method and apparatus for administering nitric oxide with supplemental drugs
DK3407900T3 (da) 2016-01-27 2024-04-02 Syk Tech Llc Apparatur til topisk anvendelse af kvældstofoxid samt fremgangsmåder
MX2020005087A (es) 2017-11-17 2020-08-13 Renovion Inc Composiciones de acido ascorbico estables y metodos de uso de las mismas.
CN109169638A (zh) * 2018-11-12 2019-01-11 苏州瑞徕生物科技有限公司 一种细胞保存液及其用途
MX2024008001A (es) 2022-01-04 2024-07-12 Renovion Inc Solucion acuosa que comprende una sal de glutation.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133584D1 (de) 1990-12-05 2007-12-13 Gen Hospital Corp Vorrichtung zum Behandeln einen Lungengefässverengung und von Asthma
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5427797A (en) 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
WO1994022306A1 (en) * 1993-04-06 1994-10-13 Brigham And Womens Hospital Nitric oxide combination therapy
US5728705A (en) 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5823180A (en) 1995-04-03 1998-10-20 The General Hospital Corporation Methods for treating pulmonary vasoconstriction and asthma
WO1996039409A1 (en) * 1995-06-05 1996-12-12 Nitromed, Inc. Nitrosylated and nitrated superoxide oxidants and reductants
ATE331505T1 (de) 1996-04-05 2006-07-15 Gen Hospital Corp Behandlung einer hämoglobinstörung
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
SE9903985D0 (sv) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
EP1246621A4 (en) * 1999-12-23 2004-11-24 Nitromed Inc NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE

Also Published As

Publication number Publication date
CA2414409A1 (en) 2002-01-03
KR20030029530A (ko) 2003-04-14
US6935334B2 (en) 2005-08-30
CN100488497C (zh) 2009-05-20
US6601580B1 (en) 2003-08-05
WO2002000175A2 (en) 2002-01-03
AU2001273622B2 (en) 2007-05-10
WO2002000175A3 (en) 2002-08-15
JP2004509850A (ja) 2004-04-02
EP1301076A4 (en) 2004-09-22
AU7362201A (en) 2002-01-08
KR100849103B1 (ko) 2008-07-30
US20030202969A1 (en) 2003-10-30
IL153702A0 (en) 2003-07-06
CN1635923A (zh) 2005-07-06
EP1301076A2 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
MXPA03000182A (es) Efectividad terapeutica de mejoria de inhalacion de oxido nitrico.
WO2001054679A3 (en) Transdermal composition containing an anesthetic and a vasodilator agent
JP2004509850A5 (es)
WO2001068040A3 (en) The use of plant extracts and sugars to protect keratinous tissue
WO2004014314A3 (en) Methods and compositions concerning poxviruses and cancer
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
TW200602350A (en) Methods and compositions for treating hepatitis C virus
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007134241A3 (en) Nasal delivery of therapeutic agents using tight junction agonists
UA90668C2 (ru) Состав для лечения хронической венозной недостаточности, который содержит водный экстракт листьев красного винограда и противовоспалительное средство
WO2001093909A3 (en) Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
IL192100A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
UA99101C2 (ru) Композиция для местного ухода за кожей, содержащая соединения глицерина ди- и моносалицилата
WO2004052308A3 (en) Topical anti-infective formulations
WO2007075695A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2004046309A3 (en) Methods for inhibiting viral replication in vivo
WO2000066107A3 (en) Antimalarian agents for the treatment of asthma
WO2004103296A3 (en) Methods of treating idiopathic pulmonary fibrosis
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
WO2004110392A3 (en) Compositions and methods for treating coronavirus infection and sars
WO2006031706A3 (en) Betulinol derivatives as anti-hiv agents
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
PT1220676E (pt) Prevencao do cancro colorrectal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal